ADCK2 and breast carcinoma: A 2022 study reported missense mutations in ADCK2 in 9.4% of breast cancer patients, whereas such mutations were relatively rare in studies of other cancers, occurring in 0–1% of endometrial carcinomas and up to 3.5% of uterine carcinomas.